Defeating a superbug: A breakthrough in vaccine design against multidrug-resistant Pseudomonas aeruginosa using reverse vaccinology
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0289609 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Sepideh Fereshteh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran. Hauptthemen laut MEDLINE: Epitopes, B-Lymphocyte, Pseudomonas aeruginosa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multidrug-resistant Pseudomonas aeruginosa has become a major cause of severe infections. Due to the lack of approved vaccines, this study has presented putative vaccine candidates against it.
Methods
P . aeruginosa 24Pae112 as a reference strain was retrieved from GenBank database. The surface-exposed, antigenic, non-allergenic, and non-homologous human proteins were selected. The conserved domains of selected proteins were evaluated, and the prevalence of proteins was assessed among 395 genomes. Next, linear and conformational B-cell epitopes, and human MHC II binding sites were determined. Finally, five conserved and highly antigenic B-cell epitopes from OMPs were implanted on the three platforms as multi-epitope vaccines, including FliC, the bacteriophage T7 tail, and the cell wall-associated transporter proteins. The immunoreactivity was investigated using molecular docking and immune simulation. Furthermore, molecular dynamics simulation was done to refine the chimeric cell-wall-associated transporter-TLR4 complex as the best interaction.
Results
Among 6494 total proteins of P . aeruginosa 24Pae112, 16 proteins (seven OMPs and nine secreted) were ideal according to the defined criteria. These proteins had a molecular weight of 110 kDa and were prevalent in ≥ 75% of P . aeruginosa genomes. Among the presented multi-epitope vaccines, the chimeric cell-wall-associated transporter had the strongest interaction with TLR4. Moreover, the immune simulation response revealed that the bacteriophage T7 tail chimeric protein had the strongest ability to stimulate the immune system. In addition, molecular docking and molecular dynamic simulation indicated the proper and stable interactions between the chimeric cell-wall-associated transporter and TLR4.
Conclusion
This study proposed 16 shortlisted proteins as promising immunogenic targets. Two novel platforms ( e . g . cell-wall-associated transporter and bacteriophage T7 tail proteins) for designing of multi-epitope vaccines (MEVs), showed the better performance compared to FliC. In our future studies, these two MEVs will receive more scrutiny to evaluate their immunoreactivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
- Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, Hamedan, Iran.
ORCID-Profile: Farzad Badmasti
Zitieren
APA
Fereshteh, S., Haririzadeh Jouriani, F., Noori Goodarzi, N., Torkamaneh, M., Khasheii, B., & Badmasti, F. (2023). Defeating a superbug: A breakthrough in vaccine design against multidrug-resistant Pseudomonas aeruginosa using reverse vaccinology. PLOS ONE. https://doi.org/10.1371/journal.pone.0289609
Vancouver
Fereshteh S, Haririzadeh Jouriani F, Noori Goodarzi N, Torkamaneh M, Khasheii B, Badmasti F. Defeating a superbug: A breakthrough in vaccine design against multidrug-resistant Pseudomonas aeruginosa using reverse vaccinology. PLOS ONE. 2023. doi:10.1371/journal.pone.0289609
BibTeX
@article{Fereshteh2023,
author = {Fereshteh, Sepideh and Haririzadeh Jouriani, Fatemeh and Noori Goodarzi, Narjes and Torkamaneh, Mahdi and Khasheii, Behnoush and Badmasti, Farzad},
title = {Defeating a superbug: A breakthrough in vaccine design against multidrug-resistant Pseudomonas aeruginosa using reverse vaccinology},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0289609}
}
EUVIMED